S
Saby George
Researcher at Roswell Park Cancer Institute
Publications - 167
Citations - 14398
Saby George is an academic researcher from Roswell Park Cancer Institute. The author has contributed to research in topics: Nivolumab & Renal cell carcinoma. The author has an hindex of 31, co-authored 138 publications receiving 10182 citations. Previous affiliations of Saby George include Memorial Sloan Kettering Cancer Center & University of Texas Health Science Center at San Antonio.
Papers
More filters
Journal ArticleDOI
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Robert J. Motzer,Bernard Escudier,David F. McDermott,Saby George,Hans J. Hammers,Sandhya Srinivas,Scott S. Tykodi,Jeffrey A. Sosman,Giuseppe Procopio,Elizabeth R. Plimack,Daniel Castellano,Toni K. Choueiri,Howard Gurney,Frede Donskov,Petri Bono,John Wagstaff,Thomas Gauler,Takeshi Ueda,Yoshihiko Tomita,Fabio A.B. Schutz,Christian Kollmannsberger,James Larkin,Alain Ravaud,Jason S. Simon,Li-an Xu,Ian M. Waxman,Padmanee Sharma +26 more
TL;DR: Overall survival was longer and fewer grade 3 or 4 adverse events occurred with nivolumab than with everolimus among patients with previously treated advanced renal-cell carcinoma.
Journal ArticleDOI
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Robert J. Motzer,Nizar M. Tannir,David F. McDermott,Osvaldo Arén Frontera,Bohuslav Melichar,Toni K. Choueiri,Elizabeth R. Plimack,Philippe Barthélémy,Camillo Porta,Saby George,Thomas Powles,Frede Donskov,V. Neiman,V. Neiman,Christian Kollmannsberger,Pamela Salman,Howard Gurney,Robert E. Hawkins,Alain Ravaud,Marc-Oliver Grimm,Sergio Bracarda,Carlos H. Barrios,Yoshihiko Tomita,Daniel Castellano,Brian I. Rini,Allen C. Chen,Sabeen Mekan,M. Brent McHenry,Megan Wind-Rotolo,Justin Doan,Padmanee Sharma,Hans J. Hammers,Hans J. Hammers,Bernard Escudier +33 more
TL;DR: Overall survival and objective response rates were significantly higher with nivolumab plus ipilimumab than with sunitinib among intermediate‐ and poor‐risk patients with previously untreated advanced renal‐cell carcinoma.
Journal ArticleDOI
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
Robert J. Motzer,Brian I. Rini,David F. McDermott,Bruce G. Redman,Timothy M. Kuzel,Michael R. Harrison,Ulka N. Vaishampayan,Harry A. Drabkin,Saby George,Theodore F. Logan,Kim Margolin,Elizabeth R. Plimack,Alexandre Lambert,Ian M. Waxman,Hans J. Hammers +14 more
TL;DR: Nivolumab demonstrated antitumor activity with a manageable safety profile across the three doses studied in mRCC, and no dose-response relationship was detected as measured by PFS.
Journal ArticleDOI
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
Robert J. Motzer,Brian I. Rini,David F. McDermott,Osvaldo Arén Frontera,Hans J. Hammers,Michael A. Carducci,Pamela Salman,Bernard Escudier,Benoit Beuselinck,Asim Amin,Camillo Porta,Saby George,Victoria Neiman,Sergio Bracarda,Scott S. Tykodi,Philippe Barthélémy,Raya Leibowitz-Amit,Elizabeth R. Plimack,Sjoukje F. Oosting,Bruce G. Redman,Bohuslav Melichar,Thomas Powles,Paul Nathan,Stéphane Oudard,David Pook,Toni K. Choueiri,Frede Donskov,Marc-Oliver Grimm,Howard Gurney,Daniel Y.C. Heng,Christian Kollmannsberger,Michael R. Harrison,Yoshihiko Tomita,Ignacio Duran,Viktor Grünwald,M. Brent McHenry,Sabeen Mekan,Nizar M. Tannir,CheckMate Investigators +38 more
TL;DR: Results showed that nivolumab plus ipilimumab continued to be superior to sunitinib in terms of overall survival and characterisation of response, and safety after extended follow-up in intermediate-risk or poor-risk patients.
Journal ArticleDOI
Featured Updates to the NCCN Guidelines
Robert J. Motzer,Eric Jonasch,M. Dror Michaelson,Lakshminarayanan Nandagopal,John L. Gore,Saby George,Ajjai Alva,Naomi B. Haas,Michael R. Harrison,Elizabeth R. Plimack,Jeffrey A. Sosman,Neeraj Agarwal,Sam B. Bhayani,Toni K. Choueiri,Brian A. Costello,Ithaar Derweesh,Thomas H. Gallagher,Steven L. Hancock,Christos Kyriakopoulos,Chad A. LaGrange,Elaine T. Lam,Clayton Lau,Bryan Lewis,Brandon Manley,Brittany McCreery,Andrew McDonald,Amir Mortazavi,Phillip M. Pierorazio,Lee Ponsky,Bruce G. Redman,Bradley G. Somer,Geoffrey Wile,Mary A. Dwyer,Lydia J. Hammond,Griselda Zuccarino-Catania +34 more
TL;DR: The major changes to the 2012 and 2011 NCCN Guidelines for Soft Tissue Sarcoma pertain to the management of patients with gastrointestinal stromal tumors and desmoid tumors.